Compare FULC & URG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FULC | URG |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.8M | 532.4M |
| IPO Year | 2019 | 2006 |
| Metric | FULC | URG |
|---|---|---|
| Price | $3.68 | $1.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $16.38 | $2.57 |
| AVG Volume (30 Days) | 3.1M | ★ 14.1M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,207,000.00 |
| Revenue This Year | N/A | $200.42 |
| Revenue Next Year | N/A | $98.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.83 | $1.12 |
| 52 Week High | $15.74 | $2.35 |
| Indicator | FULC | URG |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 36.43 |
| Support Level | $3.41 | $1.15 |
| Resistance Level | $4.02 | $1.33 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 51.96 | 15.38 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project; Shirley Basin; Other U.S. Projects.